RENE Reneuron Group Plc

TIDMRENE

RNS Number : 0132H

ReNeuron Group plc

24 July 2023

ReNeuron Group plc

("ReNeuron" or the "Company")

Notice of Annual General Meeting

ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies , announces that the Notice of Annual General Meeting ("AGM") and Form of Proxy have today been posted to shareholders and will shortly be available on the investors section of the Company's website here .

The AGM will be held at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate, London EC2N 4BQ on 22 August 2023 at 9.30 a.m.

The Board welcomes the opportunity to invite shareholders to attend the AGM in person. Persons intending to attend and vote at the meeting in person will need a QR code to access the meeting venue. Such QR code will need to be displayed on a smartphone or similar device. A QR code will be able to be obtained in advance by emailing externalproxyqueries@computershare.co.uk with your full name and email address. Please note that this email address should be used for this purpose only, and the Registrar will not be able to respond to any other form of communication or enquiry sent to this email address. Persons who have not obtained a QR code in advance will be able to obtain one at the meeting venue.

If shareholders are unable to attend the meeting in person, then they are encouraged to submit their votes by proxy by appointing the Chairman of the AGM as their proxy, so that their votes can be taken into account.

Shareholders are also encouraged to submit any questions for the Chairman to info@reneuron.com at least 48 hours prior to the Meeting. Shareholders that are able to attend the AGM in person will also have an opportunity to ask questions at the Meeting. Where appropriate, questions and answers will be collated and later published on the Company's website at www.reneuron.com.

The results of the proposed resolutions will be published on the Company website and announced via RNS as soon as practicable after the conclusion of the AGM.

ENDS

Enquiries:

 
 ReNeuron                                                                www.reneuron.com/investors 
 Iain Ross, Executive Chairman                                                      Via Walbrook PR 
 John Hawkins, Chief Financial Officer 
 
 Allenby Capital Limited (Nominated 
  Adviser and Broker)                                                           +44 (0)20 3328 5656 
 James Reeve/George Payne/Dan Dearden-Williams 
  (Corporate Finance) 
 Stefano Aquilino (Sales & Corporate 
  Broking) 
 
 Walbrook PR (Media & Investor Relations)            +44 (0)20 7933 8780 or reneuron@walbrookpr.com 
 Paul McManus / Alice Woodings                                +44 (0)7980 541 893 / +44 (0)7407 804 
                                                                                                654 
 
 

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX(TM) platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAUSANROKUBUAR

(END) Dow Jones Newswires

July 24, 2023 12:20 ET (16:20 GMT)

Reneuron (LSE:RENE)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Reneuron (LSE:RENE)
Historical Stock Chart
Von Jan 2024 bis Jan 2025